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The risk of osteoporosis in patients with chronic inflammatory neuropathy (CIN) has not been evaluated 
in detail. We conducted a population-based case-control study nested in a retrospective cohort to 
analyze osteoporosis risk among patients with CIN using a nationwide database. Patients with CIN 
based on the Korean Classification of Disease diagnostic code were included and were matched to 
controls. A Cox proportional hazards regression model was used to evaluate the effect of CIN on 
osteoporosis. After propensity score matching, 585 CIN patients and 585 controls were selected. 
Patients with CIN had an increased osteoporosis risk (hazard ratio [HR] = 2.293, 95% confidence interval 
[CI] 1.460–3.601) compared with controls. The osteoporosis risk was higher among male patients with 
CIN than among male controls (HR = 5.404, 95% CI 2.252–12.969), while there were no significant 
differences among women. Among the CIN patients, the average daily dose of corticosteroids was 
higher in those who developed osteoporosis (19.6 mg [10.8–49.3]) than those who did not (16.2 mg 
[7.2–29.1], p = 0.001). The osteoporosis risk among CIN patients is higher than among controls. High 
risk of osteoporosis in male patients may indicate that osteoporosis in CIN patients results from the 
disease itself or related treatments.
Chronic inflammatory neuropathy (CIN), which includes chronic inflammatory demyelinating polyradiculoneu-
ropathy (CIDP) and multifocal motor neuropathy (MMN), is a rare immune-mediated disease of the peripheral 
nerves that shows a progressive clinical course1–3. Patients with CIDP often develop substantial disability and 
nearly 20 to 30% of patients experience a functional status of being wheelchair bound or worse4,5. Although not 
as severe as in CIDP, MMN can also present with lower limb weakness and more than half of patients display 
abnormal gait before treatment6. Recently, we revealed that the bone mass of patients with CIDP was significantly 
lower than that of normal controls and low bone density was associated with impaired functional status7. Reduced 
bone mass, along with lower limb weakness and gait unsteadiness8, can increase the risk of fracture in patients 
with CIN.
It is important to assess the risk of osteoporosis or fracture in patients with CIN. A previous report revealed 
that over half of patients with CIDP developed osteoporosis within 3 years9. However, only a few studies with 
small study populations have assessed the risk of osteoporosis among patients with CIN, and there is a lack of 
comprehensive analyses of the effect of each risk factor on osteoporosis. This could be due to the low prevalence of 
CIN, which ranges from 1 to 4.8 per 100,000 for CIDP and 1–2 per 100,000 for MMN10–14. In order to overcome 
this limitation, a cohort study based on a large study population is required. Thus, we analyzed the occurrence of 
osteoporosis in patients with CIN using a nationwide database.
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Methods
Data resource and study population. The public medical insurance system in South Korea, known as the 
National Health Insurance Service, covers approximately 98% of the South Korean population as South Korean 
law requires every resident to be covered by this scheme15,16. Under this national insurance system, the Health 
Insurance Review and Assessment Service (HIRA) reviews and evaluates medical costs and healthcare service 
quality. Currently, HIRA provides nationwide claims data, which are collected during this process for research-
ers. HIRA claims data include age, sex, diagnoses, medical costs claimed, procedures, prescribed drugs, and a 
unique anonymous number for each patient16. The strength of HIRA data lies in the fact that the National Health 
Insurance Service covers the entire South Korean population which is ethnically homogeneous. Many popula-
tion-based studies have been conducted based on HIRA data17–19.
This is a population-based case-control study nested in a retrospective cohort using HIRA claims data col-
lected between 2007 and 2016. Patients and controls were identified based on the Korean Classification of Disease 
(KCD), which is an adapted version of International Classification of Disease (ICD). In the present study, we used 
the KCD diagnosis code G61.8 (other inflammatory polyneuropathies) to identify patients with CIN. Currently, 
the KCD format does not provide a diagnosis code solely for CIDP or MMN and these diagnoses are incorporated 
in the diagnosis of other inflammatory polyneuropathies (G61.8). For the robustness of the data, an operational 
definition of CIN was made based on the diagnosis code and the following criteria. After excluding patients 
with a pre-existing G61.8 diagnosis in 2007, we included patients with the following criteria: (1) age ≥18 years, 
(2) ≥2 G61.8 claims reported at least 90 days apart, (3) history of inpatient hospitalization or outpatient visit 
at the department of neurology or rehabilitation medicine, and (4) underwent nerve conduction studies. The 
inclusion criterion requiring ≥2 claims reported at least 90 days apart was based on a previous epidemiologic 
study and the diagnostic criteria of CIDP and MMN that require the disease duration to be ≥2 months and ≥1 
month, respectively20–22. We excluded the following people: (1) patients with a secondary cause of polyneuropathy 
that should be differentiated from CIN, including hereditary demyelinating neuropathy (G60.0), monoclonal 
gammopathy (D47.2), polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin change 
syndrome (G62.9, D47.7), drug or toxin-induced neuropathy (G62), Borrelia burgdorferi infection (A69.2), diph-
theria (A36.8), and amyloidosis (E85) and (2) patients with a diagnosis of osteoporosis before the initial diagnosis 
of CIN. For the control group, we identified patients aged ≥18 years whose claims included the diagnosis code 
of Z00.0 (general medical examination). Of these patients, those with a previous diagnosis of osteoporosis, a 
diagnosis code of G61.8, and neurologic disease that could be differentiated from CIN were excluded. The utili-
zation of and access to the HIRA database was approved by HIRA. The Severance Hospital Institutional Review 
Board approved this research (approval no. 4-2017-0318) and the study was conducted in accordance with the 
Declaration of Helsinki. Informed consent was waived due to the retrospective nature of the study.
Data collection. The primary outcome of this study was a new diagnosis of osteoporosis. Such diagnoses 
are made and entered by physicians at each site based on their clinical impression. HIRA provides guidelines 
regarding the clinical indications for conducting dual energy x-ray absorptiometry and prescribing medica-
tion for osteoporosis. It also reviews whether payment claims correctly follow these guidelines. Previous studies 
demonstrated a concordance between the HIRA database and actual diagnoses made using clinical informa-
tion23,24. Data regarding the basic demographics (age and sex), past medical history, and Charlson comorbidity 
index (CCI) score were collected. CCI is the most widely used comorbidity index; it categorizes comorbidities 
of patients based on the ICD codes and calculates a comorbidity score by summing the score of each category 
weighted according to the adjusted risk of mortality. A higher CCI score indicates greater comorbidities25. In the 
current study, CCI score was measured according to the algorithms suggested by Jang et al., which is based on the 
algorithm of Quan et al.24,26. The use of corticosteroids, intravenous immunoglobulin, immunosuppressants, or 
immunomodulatory drugs (alemtuzumab, azathioprine, cyclophosphamide, cyclosporine, etanercept, interferon, 
mycophenolate mofetil, methotrexate, and rituximab) were recorded. In South Korea, intravenous immunoglob-
ulin obtained reimbursement approval for use in patients with CIDP in June 2015 and in the patients with MMN 
in April 2018. As medical service providers have processed claims for insurance benefits since this time point, the 
intravenous immunoglobulin prescription data before this point or unclaimed prescriptions after this point were 
not recorded in the HIRA database and could not be analyzed in the present study. Corticosteroid doses were 
converted to the prednisone equivalent dose, and the average daily dose of corticosteroid was calculated by divid-
ing the cumulative prednisone dose by the duration of treatment. Pulsed dexamethasone treatment was defined 
as the prescription of ≥40 mg dexamethasone for ≥4 consecutive days and pulsed methylprednisolone treatment 
was defined as the prescription of ≥500 mg methylprednisolone for ≥4 consecutive days27,28. The annual inci-
dence and prevalence was calculated by using patients of all ages. The annual incidence and prevalence of CIN 
was calculated by dividing the number of newly diagnosed patients with CIN and the number of the patients who 
visited healthcare facilities with a diagnosis of CIN by the population of each year, respectively. The total popula-
tion of South Korea was obtained from the Korean Statistical Information Service (KOSIS; http://kosis.kr/), which 
provides official statistics for South Korea.
Propensity score matching. Osteoporosis is associated with age and sex29. Therefore, a propensity score 
matching technique was adopted to attenuate the compounding effects of age, sex, index year, and CCI score 
between patients with CIN and controls. The propensity score was calculated using a logit model for matching 
variables (age, sex, index year, and CCI score) by considering patients with CIN as the treatment group and 
predicting probabilities. A 1:1 propensity score matching was fulfilled to match patients with CIN with controls 
within a caliper of 0.05. Propensity score matching revealed that there were no significant differences in age, sex, 
and CCI score between the groups. A total of 1170 participants (585 patients with CIN and 585 controls) were 
used in the final analysis.
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Statistical analysis. The results are presented as numbers (percentages) for categorical variables and median 
[Q1–Q3] for continuous variables as these did not meet the normality assumption. For data before propensity 
score matching, the Chi-square test and Mann–Whitney U test were used for the comparison of categorical var-
iables and continuous variables between the 2 groups, respectively. For data after propensity score matching, 
the McNemar test and the Wilcoxon signed rank test were used for the comparison of categorical variables and 
continuous variables between the 2 groups, respectively. We used a stratified Cox proportional hazards regression 
model to estimate the effect of CIN on the development of osteoporosis when taking the matching into account. 
Kaplan–Meier analysis was performed to analyze the cumulative incidence curve of osteoporosis between patients 
with CIN and controls. The log-rank test was performed to assess the difference in the incidence curves between 
the 2 groups. All p-values were two-sided and a p value < 0.05 was considered statistically significant. SAS 9.4 
software (SAS Institute, Cary, NC) was used for the statistical analysis. R software (version 3.4.0, R Foundation for 
Statistical Computing, Vienna, Austria) was used to draw the cumulative incidence curves.
Results
Baseline demographics and clinical features of CIN and control groups. After excluding patients 
with pre-existing CIN in 2007, a total of 2643 patients with a diagnosis code of other inflammatory polyneurop-
athy (G61.8) were identified between 2008 and 2016. Of these, 858 fulfilled the inclusion criteria. The exclusion 
criteria applied to a further 158 patients. Finally, 700 patients who satisfied the operational definition of CIN were 
included in the study (Fig. 1). The annual incidence of CIN was 0.2 per 100,000 per year and prevalence rate was 
0.6 per 100,000 population. Baseline demographic and clinical characteristics of patients with CIN and controls 
are presented in Table 1. There were 427 (61.0%) male and 273 (39.0%) female participants with CIN with a male 
to female ratio of 1.6:1. There was significant difference in terms of sex (p < 0.001) and CCI score (p < 0.001) 
between the CIN and control groups before propensity score matching. Using propensity score matching, 585 
patients with CIN and 585 controls were finally used in the analysis and it was confirmed that there were no sig-
nificant differences in age, sex, and CCI scores between the 2 groups.
Incidence of osteoporosis in CIN and control groups. Cumulative incidences of 1) osteoporosis and 
2) osteoporosis and/or any fracture for the CIN group and control group are shown in Fig. 2. The cumulative 
incidences of osteoporosis and osteoporosis/fracture were significantly higher among patients with CIN than 
among controls. Patients with CIN had a 2.293-fold (hazard ratio [HR] = 2.293, 95% confidence interval [CI] 
1.460–3.601) increased risk of developing osteoporosis compared with controls (Table 2). Patients with CIN also 
had an increased risk of developing any fracture (HR = 1.753, 95% CI 1.178–2.608) and osteoporosis and/or frac-
ture (HR = 1.943, 95% CI 1.411–2.678). We further evaluated the risk of osteoporosis in subgroups of patients 
stratified by age and sex. In the sex-specific analysis, osteoporosis occurred in 10% of male patients with CIN and 
15.7% of female patients with CIN. The risk of osteoporosis was significantly higher among male patients with 
CIN than among male controls (HR = 5.404, 95% CI 2.252–12.969). Conversely, there were no significant differ-
ences in the risk of osteoporosis between female patients with CIN and female controls.
Figure 1. Flowchart of case inclusion process. NR, department of neurology; RH, department of rehabilitation 
medicine; NCS, nerve conduction study; CIN, chronic inflammatory neuropathy.
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Comparison between male and female patients with CIN. We compared the clinical factors between 
male and female patients with CIN to evaluate the possible factors that may have affected the high risk of oste-
oporosis among male patients with CIN (Table 3). Male patients with CIN were older than female patients with 
CIN (p = 0.022) and had a higher CCI score (p = 0.006). With regard to comorbidities, the prevalence of diabetes 
mellitus, liver disease, and cerebrovascular disease was higher among male patients with CIN than among female 
patients (p = 0.020, p = 0.003 and p = 0.003, respectively). There were no significant differences in the use of cor-
ticosteroids and immunosuppressive or immunomodulating agents between male and female patients.
Comparison between patients with CIN who developed osteoporosis and those who did 
not. We compared clinical factors between 72 patients with CIN who developed osteoporosis (osteoporosis 
group) and 513 patients with CIN who did not (non-osteoporosis group). The results are shown in Table 4. The 
proportion of female patients was significantly higher in the osteoporosis group than in the non-osteoporosis 
group (p = 0.038). Regarding treatment, the average daily dose of corticosteroids within 12 months from CIN 
diagnosis was significantly higher in the osteoporosis group than in the non-osteoporosis group (p = 0.001). The 
difference was found to be significant in terms of the average daily dose of oral prednisolone (p < 0.001), whereas 
Before matching After matching
CIN Control
P-value
CIN Control
P-value(n = 700) (n = 26908) (n = 585) (n = 585)
Age, years 55.0 [44.0–66.0]
56.0 
[45.0–68.0] 0.060
55.0 
[43.0–66.0]
56.0 
[43.0–68.0] 0.139
Sex <0.001 0.882
  Women 273 (39.0) 13321 (49.5) 235 (40.2) 233 (39.8)
  Men 427 (61.0) 13587 (50.5) 350 (59.8) 352 (60.2)
CCI score <0.001 0. 780
  0 132 (18.9) 8347 (31.0) 132 (22.6) 132 (22.6)
  1 137 (19.6) 6218 (23.1) 120 (20.5) 130 (22.2)
  ≥2 431 (61.6) 12343 (45.9) 333 (56.9) 323 (55.2)
Median CCI score 2.0 [1.0–4.0] 1.0 [0–3.0] <0.001
2.0 
[1.0–4.0]
2.0 
[1.0–4.0] 0.895
Treatment
  IVIG* 31 (4.4) 29 (5.0)
  Corticosteroid 600 (85.7) 501 (85.6)
  Immunosuppressant 304 (43.4) 253 (43.3)
Table 1. Baseline demographic and clinical characteristics of patients with chronic inflammatory neuropathy 
and controls before and after propensity score matching. *Intravenous immunoglobulins that have been 
prescribed and claimed since June 2015. Data are expressed as count (percentage) or median [Q1–Q3] 
values. CCI, Charlson comorbidity index; CIN, chronic inflammatory neuropathy; IVIG, intravenous 
immunoglobulin.
Figure 2. Cumulative incidence curves: (A) osteoporosis and (B) osteoporosis and/or fracture for chronic 
inflammatory neuropathy (CIN) and control groups.
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no difference was observed in the dose of pulsed methylprednisolone (p = 0.842). Conversely, the proportion 
of patients who received intravenous immunoglobulin or immunosuppressive agents was significantly lower in 
the osteoporosis group than in the non-osteoporosis group (p = 0.038 and p = 0.020, respectively). In terms of 
preventive therapy, 38.9% of patients with osteoporosis and 23.4% of patients without osteoporosis were treated 
with vitamin D and/or calcium.
Discussion
The present study revealed a high risk of osteoporosis among patients with CIN based on nationwide cohort. The 
results showed that patients with CIN had a 2.293-fold increased risk of osteoporosis compared with matched 
controls. Although osteoporosis is frequent among women in general, the risk of osteoporosis was significantly 
higher among male patients with CIN than among male controls. These results highlight the importance of early 
screening to detect osteoporosis in both male and female patients with CIN. In addition, patients with CIN who 
Characteristics
CIN Control CIN vs. control
Total Case (%) Total Case (%) HR 95% CI P-value
Outcomes
  Osteoporosis 585 72 (12.3) 585 28 (4.8) 2.293 1.460–3.601 <0.001
  Fracture 585 74 (12.6) 585 37 (6.3) 1.753 1.178–2.608 0.006
  Osteoporosis or 
fracture 585 124 (21.2) 585 58 (9.9) 1.943 1.411–2.678 <0.001
Occurrence of osteoporosis
Sex
  Men 350 35 (10.0) 352 6 (1.7) 5.404 2.252–12.969 <0.001
  Women 235 37 (15.7) 233 22 (9.4) 1.41 0.809–2.459 0.225
Age, years
  18–49 228 22 (9.7) 213 5 (2.4) 3.684 1.375–9.873 0.010
  ≥50 357 50 (14.0) 372 23 (6.2) 2.027 1.211–3.391 0.007
Table 2. Hazard ratios for osteoporosis and/or fracture in patients with chronic inflammatory neuropathy and 
the risk of osteoporosis stratified by age and sex. Data are expressed as count (percentage) values. CIN, chronic 
inflammatory neuropathy; HR, hazard ratio; CI, confidence interval.
Male 
(n = 350)
Female 
(n = 235) P-value
Age, years 56.0 [45.0–66.0]
53.0 
[39.0–64.0] 0.022
CCI score 0.013
  0 73 (20.9) 59 (25.1)
  1 61 (17.4) 59 (25.1)
  ≥2 216 (61.7) 117 (49.8)
Median CCI score 2.0 [1.0–4.0] 1.0 [0–3.0] 0.006
Past medical history
  Connective tissue disease 15 (4.3) 18 (7.7) 0.083
  Diabetes mellitus 148 (42.3) 77 (32.8) 0.020
  Renal disease 32 (9.1) 12 (5.1) 0.070
  Liver disease 84 (24.0) 33 (14.0) 0.003
  Cerebrovascular disease 84 (24.0) 33 (14.0) 0.003
  Cancer 47 (13.4) 21 (8.9) 0.097
  Metastatic cancer 9 (2.6) 6 (2.6) 0.989
Number of patients using 
corticosteroids 306 (87.4) 195 (83.0) 0.132
Average daily dose ≤ 12 m 
from onset
17.5 
[7.5–31.3]
15.8 
[7.6–31.5] 0.478
Number of patients using 
IVIG* 13 (3.7) 16 (6.8) 0.091
Number of patients using 
immunosuppressant 151 (43.1) 102 (43.4) 0.950
Table 3. Comparison of clinical and treatment-related features between male and female patients with chronic 
inflammatory neuropathy. *Intravenous immunoglobulins that have been prescribed and claimed since June 
2015. Data are expressed as count (percentage) or median [Q1–Q3] values. CCI, Charlson comorbidity index; 
IVIG, intravenous immunoglobulin.
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developed osteoporosis received higher doses of corticosteroids than controls, which may suggest that high dose 
corticosteroid use is one of the risk factors for osteoporosis among patients with CIN.
Only a few studies have evaluated the occurrence of osteoporosis among patients with CIN, with varying 
results7,9,30. One study evaluated bone mineral density in 9 patients with CIDP during pulsed steroid treatment 
and 5 (55.6%) patients developed osteoporosis over 3 years9. Our recent retrospective study also demonstrated 
that 39.0% of CIDP patients had a bone mineral density in the osteoporotic range7. In contrast, another study that 
measured bone mineral density during pulsed steroid treatment in 40 patients with CIDP reported that none of 
the patients developed osteoporosis after 12 months30. Previous results are based on small study populations with 
a short follow-up duration and it is difficult to determine whether patients with CIN have an increased risk of 
osteoporosis compared with those without CIN. Therefore, a population-based study with an adequate follow-up 
period is necessary to assess the risk of osteoporosis for this relatively uncommon disease.
The high incidence of osteoporosis among patients with CIN may result from prolonged use of corticoster-
oids, which causes bone loss by inhibiting osteoblast function and increasing osteoclast formation31,32. In the pres-
ent analysis, patients with CIN who developed osteoporosis received higher doses of steroids than those who did 
not. In addition, the difference was attributed to the difference in the dose of oral prednisolone but not to the dose 
of intravenous pulsed steroids. This is consistent with previous reports showing that the cumulative steroid dose 
is inversely correlated with bone mineral density and that prolonged oral steroid treatment is more deleterious to 
bone density than pulsed intravenous administration31,33,34. In contrast, patients who did not develop osteoporo-
sis were more likely to have undergone treatment with immunosuppressive agents or intravenous immunoglobu-
lin. The steroid-sparing effect of these alternative treatments may have reduced the risk of osteoporosis, although 
further studies are required to investigate this.
There are some other possible explanations for the high incidence of osteoporosis in patients with CIN. First, 
functional disability resulting from CIN may have an adverse effect on bone density. Previous studies showed 
that 39.5% of patients with CIDP had a functional status of chair-bound or worse at the time of initial treatment5, 
Osteoporosis
Non-
osteoporosis
P-value(n = 72) (n = 513)
Age, years 57.0 [44.0–64.0]
54.0 
[43.0–66.0] 0.378
Sex 0.038
  Female 37 (51.4) 198 (38.6)
  Male 35 (48.6) 315 (61.4)
Median CCI score 2.0 [0–3.0] 2.0 [1.0–4.0] 0.479
Past medical history
  Connective tissue disease 5 (6.9) 28 (5.5) 0.585
  Diabetes mellitus 26 (36.1) 199 (38.8) 0.662
  Renal disease 2 (2.8) 42 (8.2) 0.103
  Liver disease 11 (15.3) 106 (20.7) 0.285
  Cerebrovascular disease 16 (22.2) 101 (19.7) 0.615
  Cancer 10 (13.9) 58 (11.3) 0.522
  Metastatic cancer 3 (4.2) 12 (2.3) 0.413
Number of patients using corticosteroids 64 (88.9) 437 (85.2) 0.401
Average daily dose ≤12 m from onset 19.6 [10.8–49.3]
16.2 
[7.2–29.1] 0.001
Pulsed methylprednisolone during follow-up 22 (30.6) 178 (34.7) 0.488
  Total dose, mg
6250.0 
[3750.0–
6250.0]
6250.0 
[3750.0–
6250.0]
0.842
Oral prednisolone during follow-up 61 (84.7) 404 (78.8) 0.240
  Average daily dose, mg 14.6 [8.7–31.8] 4.9 [1.8–10.0] <0.001
Number of patients using IVIG* 0 (0) 29 (5.7) 0.038
Number of patients using immunosuppressant 22 (30.6) 231 (45.0) 0.020
  Azathioprine 18 (25.0) 191 (37.2) 0.043
  Cyclosporine 0 (0) 24 (4.7) 0.060
  Cyclophosphamide 2 (2.8) 25 (4.9) 0.561
  Mycophenolate mofetil 3 (4.2) 43 (8.4) 0.213
  Methotrexate 1 (1.4) 9 (1.8) >0.999
Table 4. Comparison of clinical and treatment-related feature between patients with chronic inflammatory 
neuropathy who developed osteoporosis and those who did not. *Intravenous immunoglobulins that have been 
prescribed and claimed since June 2015. Data are expressed as count (percentage) or median [Q1–Q3] values. 
CCI, Charlson comorbidity index; IVIG, intravenous immunoglobulin.
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and more than half of the patients with MMN displayed abnormality in gait before treatment6. This disability 
can result in decreased muscle mass, lack of physical activity, and low sunlight exposure, all of which are known 
risk factors for bone loss35–37. Concordantly, our recent study revealed that osteoporosis among patients with 
CIDP was associated with impaired functional status7. Second, CIN itself can cause bone loss. Previous stud-
ies have revealed an increased risk of osteoporosis among patients with autoimmune neurological diseases38–40. 
Chronic inflammation in these diseases is thought to promote bone loss through pro-inflammatory cytokines by 
inhibiting osteoblast activity and promoting osteoclast activity41,42. Interleukin-17 is one of the proinflammatory 
cytokines that contributes to bone loss43, and interleukin-17 levels were found to be high in both active CIDP 
patients and in an animal model of CIDP44,45. In addition, tumor necrosis factor alpha (TNF-α), which is known 
to induce osteoclastogenesis, plays a main role in animal models of autoimmune neuropathy, and autoimmune 
neuritis was attenuated in TNF-α knockout mice, probably by altering the balance between proinflammatory and 
anti-inflammatory macrophages46–48.
It is interesting to note that the risk of osteoporosis was especially high among male patients with CIN. In 
general, women have a significantly higher risk of osteoporosis than men, and the rate of osteoporosis among 
women aged ≥50 years is nearly 4 times higher than that among men29. Thus, although the absolute proportion 
of patients with CIN with newly developed osteoporosis was higher among women than among men, the relative 
risk was not significantly different from that among controls because of the high baseline risk among the general 
female population. In contrast, the risk of osteoporosis among male patients with CIN was significantly higher 
than that among controls. This may reflect both a low incidence of osteoporosis among the general male popu-
lation and an increased risk of osteoporosis among male patients with CIN. Overall, the male to female ratio of 
osteoporosis occurrence in patients with CIN was not as markedly different as in controls. This finding may imply 
that the development of osteoporosis in both male and female patients with CIN is attributable to a common 
factor: this could be CIN itself, disability from the disease, or related treatments.
The high risk of osteoporosis or fracture in male patients with CIN may be partially due to an older age or a 
higher proportion of diabetes mellitus among male patients with CIN compared with female patients. Previous 
studies revealed that male patients with CIDP were older than female patients with CIDP. One study reported 
that the prevalence of CIDP was higher among male than female patients, particularly those over the age of 55 
years12. Other studies showed that the prevalence of CIDP continuously increased after the age of 60–70 years 
among male patients with CIDP, while the prevalence started to decrease from this point in female patients11,13. 
The risk of osteoporosis increases with age29 and older age in male patients with CIN may further increase the risk 
of osteoporosis. In addition, diabetes mellitus was observed more frequently among male patients with CIN than 
among female patients, which is consistent with the previous studies49,50. Patients with type 1 diabetes mellitus 
have decreased bone mineral density51,52, and the risk of fracture is increased among patients with type 2 diabe-
tes mellitus53. Thus, the higher incidence of fracture may result from the higher proportion of diabetes mellitus 
among male patients with CIN.
Despite a high incidence of osteoporosis among patients with CIN, only 38.9% of patients were treated with 
Vitamin D and/or calcium. Recent guidelines recommend that all adults taking ≥2.5 mg/day of prednisone for 
more than 3 months should take optimal doses of calcium and vitamin D54. However, not enough attention is 
paid to the risk of osteoporosis in patients taking corticosteroids. Hougardy et al. showed that only 31% of those 
taking oral corticosteroids over a prolonged period were given medication to prevent osteoporosis55. A previous 
survey conducted by the Korea Centers for Disease Control & Prevention similarly showed that less than half of 
women over 50 diagnosed with osteoporosis were being treated56. Lack of awareness has been similarly observed 
among neurologists. In previous studies regarding bone health in patients with myasthenia gravis, only half of 
patients undergoing corticosteroid treatment were treated with bisphosphonates57,58. In addition, previous studies 
show that the physician diagnosis rate and treatment rate of osteoporosis is lower for male patients than female 
patients55,59. Thus, the current study may contribute to raising awareness among neurologists regarding bone loss 
in patients with CIN, especially in male patients.
Some limitations to this study should be acknowledged. First, the results are based on the HIRA data, which 
are obtained for the purposes of administrative billing. We were unable to assess risk factors for osteoporosis that 
are not collected in the HIRA database. Second, data regarding the clinical features, laboratory results, disease 
course and severity, and results of nerve conduction studies, as well as bone mineral density and biochemical 
parameters, are not provided in the HIRA data. Therefore, the diagnosis of CIN and osteoporosis had to rely upon 
the KCD diagnosis code and operational definition. However, the demographic characteristics of patients with 
CIN in the present study, including age, gender ratio, and annual incidence, correlates well with those reported in 
previous studies10–13,60, which may imply that the diagnosis is reliable. In addition, previous reports demonstrated 
a considerable correlation between prevalence calculated based on the HIRA database and actual diagnoses made 
using clinical data23,24. Third, the use of prophylactic therapy with vitamin D or calcium could not be adequately 
analyzed. In contrast to the other medications, including steroids and immunosuppressive agents, calcium and 
vitamin D supplements are available to the patients without prescription. As the current study is based on the 
data obtained for the purposes of administrative billing, the use of medications without prescription could not 
be analyzed.
In conclusion, this nationwide, population-based study showed that the risk of osteoporosis among patients 
with CIN is significantly higher than among matched controls. The risk was particularly high among male 
patients with CIN, who are usually perceived to have a lower risk of osteoporosis than female patients. Moreover, 
it was found that not enough patients were taking preventive treatment for osteoporosis. The result highlights the 
importance of early screening for osteoporosis and initiating (or switching) pharmacologic treatment for osteo-
porosis in patients with CIN.
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Data Availability
Data are available at Healthcare Bigdata Hub (http://opendata.hira.or.kr) after the qualification process and 
approval from HIRA for the utilization of and access to the HIRA database.
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